METHODS OF DETERMINING THE PRESENCE AND/OR CONCENTRATION OF AN ANALYTE IN A SAMPLE

• US 20120115248A1
• Filed: 01/03/2012
• Published: 05/10/2012
• Est. Priority Date: 07/01/2009
• Status: Abandoned Application

• Current Assignee: Henry Ford Health System, Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Henry Ford Health System
• Inventors: Yang, Youjun, Szamosfalvi, Balazs, Yee, Jerry, Frinak, Stanley, Ansyln, Eric V.
• Application Number:
  US13/342,598
• Publication Number:
  US 20120115248A1
• Time in Patent Office: Days
• US Class Current: 436/501
• CPC Class Codes: C12Q 1/00 Measuring or testing processes involving enzymes, nucleic acids or microorganisms measuring or testing apparatus with condition measuring or sensing means, e.g. colony counters, C12M1/34; Compositions therefor; Processes of preparing such compositions
• CPC Class Codes: G01N 33/84 involving inorganic compounds or pH
• CPC Class Codes: G01N 35/085 Flow Injection Analysis

Abstract

Compositions, methods, and systems for monitoring analyte levels are provided herein. The disclosure provides methods and systems for the real-time monitoring of analytes, such as citrate, calcium, phosphate and magnesium, in a biological fluid in a clinical setting.

Claims

1. A method comprising:

providing an analyte;

providing an analyte receptor and an indicator, wherein at least a portion of the analyte receptor and the indicator form a receptor/indicator complex;

contacting the receptor/indicator complex with the analyte; and

allowing the analyte to interact with the receptor/indicator complex so as to generate a detectable signal.

2. The method of claim 1 wherein the analyte is present in a biological fluid.

3. The method of claim 2 further comprising monitoring a concentration level of the analyte present in the biological fluid.

4. The method of claim 2 wherein the biological fluid comprises an extracorporeal blood circuit effluent fluid produced on a hemofilter or a dialyzer device with hemofiltration or dialysis or any combination of these two processes.

5. The method of claim 1 further comprising detecting the detectable signal by using a Flow Injection Analysis instrument.

6. The method of claim 1 further comprising correlating the detectable signal with a calibration curve to determine a concentration of the analyte.

7. The method of claim 1 wherein the analyte is selected from the group consisting of:

ionized calcium, citrate, phosphate, magnesium, and combinations thereof.

8. The method of claim 1 wherein allowing the analyte to interact with the receptor/indicator complex comprises allowing the analyte to displace at least a portion of the indicator in the receptor/indicator complex to form a receptor/analyte complex.

9. The method of claim 1 wherein allowing the analyte to interact with the receptor/indicator complex comprises allowing the analyte to bind to the receptor/indicator complex.

10. The method of claim 1 wherein the indicator comprises at least one indicator selected from the group consisting of:

a chromophore, a fluorophore, alizarin complexone, 5-carboxyfluorescein, pyrocatechol violet, xylenol orange, and combinations thereof.

11. The method of claim 1 wherein the analyte receptor is Fura-2 or

12. The method of claim 1 further comprising using a mathematical treatment to extrapolate the concentration of the analyte.

13. The method of claim 12 wherein the mathematical treatment comprises an artificial neural network (ANN).

14. A system comprising:

a receptor/indicator complex comprising an analyte receptor and an indicator; and

an analyte, wherein the analyte will displace the indicator in the receptor/indicator complex; and

wherein the displaced indicator will generate a detectable signal.

15. The system of claim 14 wherein the analyte is present in a biological fluid.

16. The system of claim 14 wherein the analyte is present in a biological fluid, and wherein the biological fluid is an extracorporeal blood circuit effluent fluid produced on a hemofilter or dialyzer device with hemofiltration or dialysis or any combination of these two processes.

17. The system of claim 14 further comprising a Flow Injection Analysis instrument.

18. The system of claim 14 wherein the analyte is selected from the group consisting of:

ionized calcium, citrate, phosphate, magnesium, and combinations thereof.

19. The system of claim 14 wherein the indicator comprises at least one indicator selected from the group consisting of:

a chromophore, a fluorophore, alizarin complexone, 5-carboxyfluorescein, pyrocatechol violet, xylenol orange, and combinations thereof.

20. The system of claim 14 wherein the analyte receptor is Fura-2 or

21. The system of claim 14 further comprising one or more of a computer, a wireless network, a hemodialyzer, a plasma flow sensor, a detector, a UV-Vis spectro-photometer, a flow cell, a syringe pump, a multiposition valve, and a peristaltic pump.